Clinical trials for lung cancer
164 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
AstraZeneca
AstraZeneca
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
AstraZeneca
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
Janssen
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
1
Targeted therapy
Systemic Treatment-Naive
Janssen
Janssen
Phase 3
Lung cancer
#NCT05215340
#2023-507933-12-00
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
ALK
BRAF
EGFR
MET
NTRK-1/2/3
RET
ROS-1
Immunotherapy
Targeted therapy
Antibody Drug Conjugates (ADC)
Immunotherapy
Chemotherapy
Targeted therapy
Antibody Drug Conjugates (ADC)
Institut Bergonié (Bordeaux), Centre Hospitalier Universitaire de Lille (Lille), Centre Hospitalier Universitaire de Montpellier - Site Arnaud de Villeneuve (Montpellier), Hôpital Tenon AP-HP (Paris ), Hôpital Foch (Suresnes) (and 8 more...)
Daiichi Sankyo
Phase 3
Lung cancer
#NCT05899608
#2024-513087-26-00
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Non-squamous NSCLC
Metastatic
None
Systemic Treatment-Naive
CHU de Rennes - Hôpital Pontchaillou (Rennes), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Centre François Baclesse (Caen ), Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier) (and 10 more...)
Summit Therapeutics
Phase 3
Lung cancer
#NCT05502237
#2023-509825-38-00
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
Systemic Treatment-Naive
ALK
BRAF
EGFR
NTRK-1/2/3
RET
ROS-1
Immunotherapy
Immunotherapy
Chemotherapy
Targeted therapy
Antibody Drug Conjugates (ADC)
Hôpital Nord de Marseille (Marseille Cedex 20), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Hôpital d'instruction des Armées Bégin (Saint-Mandé), Clinique Victor Hugo - Elsan (Le Mans)
Gilead Sciences
Phase 3
Lung cancer
#NCT04613596
#2023-508922-83-00
[KRYSTAL-7] Essai sur l'ADAGRASIB en association chez des patients présentant une mutation KRAS G12C
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
KRAS G12C
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier), Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), Hôpital Ambroise-Paré AP-HP (Boulogne-Billancourt), Centre Hospitalier Universitaire de Grenoble (La Tronche), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain) (and 2 more...)
Mirati Thérapeutique Inc.
Phase 3
Lung cancer
#NCT06117774
#2023-506235-15-00
SCLC (Small Cell Lung Cancer)
Localized
None
Chemotherapy
Radiotherapy
EGFR
Bispecific T-cell engager antibodies
Hôpital Bichat - Claude Bernard - AP-HP (Paris), Hôpital Nord de Marseille (Marseille Cedex 20), Hôpitaux Nord-Ouest - Villefranche-sur-Saône (Gleizé), CHU Nice Hôpital l'Archet (Nice)
Amgen
Phase 3
Lung cancer
#NCT06908993
#2024-519971-25-00
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
MET
1
2
Immunotherapy
Chemotherapy
ALK
BRAF
EGFR
HER2
KRAS non G12C
RET
ROS-1
Systemic Treatment-Naive
Targeted therapy
Hôpital Cochin (Paris ), Centre Hospitalier Universitaire de Lille (Lille), Centre Hospitalier Départemental de Vendée (La Roche-sur-Yon), Hôpital Tenon AP-HP (Paris ), CHU - Haut-Lévêque - Bordeaux (Pessac) (and 25 more...)
Intergroupe Francophone de Cancérologie Thoracique